Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral activity and safety of CAB+RPV long-acting administered every 2 months (Q2M) in adults living with HIV-1 who previously received daily oral CAB+R...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Anthony, Richmond, Gary J., Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Margolis, David A., Sutton, Kenneth C., Wilches, Viviana, Hatch, Sarah, Roberts, Jeremy, McCoig, Cynthia, Garris, Cindy, Vandermeulen, Kati, Spreen, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711606/
https://www.ncbi.nlm.nih.gov/pubmed/34652287
http://dx.doi.org/10.1097/QAD.0000000000003085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711606/
https://www.ncbi.nlm.nih.gov/pubmed/34652287
http://dx.doi.org/10.1097/QAD.0000000000003085

Ejemplares similares